All News

Versantis Presents New VS-01 Data at The International Liver Congress 2022

Versantis Awarded Innosuisse Grant of CHF475,000 to Develop Point of Care Device to Monitor Blood Ammonia in Liver Disease Patients

Versantis Welcomes Stan Bukofzer, MD, as Scientific Advisor

Versantis to Present at the H.C. Wainwright Bioconnect Virtual Conference

Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

Versantis to Present Positive Phase 1b Data at AASLD for VS-01 in Patients with Decompensated Cirrhosis

Versantis Selected as One of the Five Leading Companies in the Field of Liposomes

These Five Companies Are Changing the Pharma Industry Through Liposomes

Versantis Appoints Leading Hepatologist Prof Dr Katharina Staufer as Chief Medical Officer

Versantis selected among the top 25 Scale-up companies in Switzerland

Versantis Receives U.S. FDA Orphan Drug Designation for VS-01

Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis

Versantis Appoints Seasoned Pharma Executive Christopher Seaton to Board

Versantis Receives FDA Rare Pediatric Disease Designation for VS-01 for the Treatment of Urea Cycle Disorders

Versantis ranked in the Top5 best Swiss startups

Versantis selected by innovation analysts from StartUS Insights as a Top 5 Orphan Drug Startup company impacting the Pharma Industry today

Versantis' main patent allowed in the USA

Versantis closes CHF 16M Series B financing round to advance clinical development of novel therapeutics for liver disease

Successful initiation for FiH Study with VS-01

Versantis is celebrating its 4th birthday!

Main patent for VS-01 granted in two additional countries.

Versantis Strengthens Leadership Team with Appointment of Dr. Med.Sophie Biguenet as Chief Medical Officer

Versantis Establishes Medical Advisory Board comprising five notorious international authorities in hepatology, intensive care, and nephrology. They joined versantis to transform the care of acute liver diseases.

Versantis welcomes Dr. Rekha Johnson on board as Senior Clinical Manager

Versantis welcomes Prof. Jonel Trebicka as Medical Lead

Versantis main patent granted in Canada

Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure

VERSANTIS RAISES CHF 4.4 MILLION IN SERIES A FINANCING TO ADVANCE NEW GENERATION OF LIVER DISEASE MEDICINES

Versantis' main patent granted in Japan

The EMA issued a positive opinion on the orphan drug designation for VS-01 for the treatment of acute liver failure.

Versantis selected for MassChallenge 2016 Accelerator

Versantis awarded with CTI Start-up Label, a seal of quality and maturity.

The first and main patent of Versantis granted

Versantis to have its first scientific advice meeting with the EMA in Apr 2016

Versantis initiates the manufacturing scale up of VS-01

Versantis receives the SME status and is now eligible for all associated incentives

Versantis attends an Innovation Task Force meeting at the EMA and consolidated its preclinical, clinical, and regulatory plan.

Versantis is a finalist of the Wellcome Translation Award

Versantis secured seed funding to complete the R&Dfor its first product VS-01

Versantis was incorporated

Versantis wins the CHF 100'000.- prize of Venture Kick Stage 3

Prof JC Leroux receives the support of CHF 50'000.- from the OPO-Stiftung

Versantis receives the support of CHF 100'000.- from the Volkswirtschaft-Stiftung